Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Russ Lehrman
AddedMar 31, 2024
UpdatedMay 31, 2026
Russ Lehrman

Russ Lehrman

Co-Founder, Bio-Nems

CrunchbaseLinkedIn

Russ Lehrman's Career

Bio-Nems
Bio-Nems

Broomfield, CO, US

Co-Founder
BioSuperior
BioSuperior

Los Altos, CA, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Russ Lehrman's Career

Bio-Nems
Bio-Nems
Angel$1.2M72011Broomfield, CO, US
Co-Founder

Leadership at Bio-Nems

Gabriel MatusGabriel MatusCo-Founder
David MedinDavid MedinCEO

Similar to Bio-Nems

BioDatomicsBioDatomicsBethesda, MD, USSoftwareest. 2010BioDatomicsBethesda, MD, US · est. 2010

BioDatomics: Advanced software tool for omics research, simplifying complex bio-research since 2010.

Seed · $1.5M30
NemaLifeNemaLifeLubbock, TX, USAI-TechBio Platformest. 2018NemaLifeLubbock, TX, US · est. 2018

NemaLife: Affordable AI-techbio platform offering early-stage in vivo testing and data for diverse industries.

Angel · $320k15
CanomiksCanomiksRochester, MN, USFormulation, Product Safetyest. 2016CanomiksRochester, MN, US · est. 2016

Canomiks' AI-driven platform enhances product safety and efficacy using genomics and bioinformatics.

Angel · $376k7
NouBioNouBioLos Angeles, CA, USBiotechest. 2022NouBioLos Angeles, CA, US · est. 2022

NouBio Inc offers sustainable, animal-free tech solutions for cultivated meat biomanufacturing, reducing production costs by 95%.

Pre-Seed · $200k3
BioSuperior
BioSuperior
Angel$256k62017Los Altos, CA, US
Founder

Similar to BioSuperior

Surf BioSurf BioPalo Alto, CA, USTherapeuticsest. 2021Surf BioPalo Alto, CA, US · est. 2021

Surf Bio: A preclinical biopharma innovating enhanced therapies for diverse diseases using next-gen surfactant.

Seed · $16M7
Superior BiologicsSuperior BiologicsHawthorne, NY, USPharmaceuticalsest. 2012Superior BiologicsHawthorne, NY, US · est. 2012

Superior Biologics, Inc.: A US-based pharmaceutical company specializing in pediatric and adult healthcare.

Late Stage Private · $185.6M200
Alveolus BioAlveolus BioBirmingham, AL, USBiotherapeuticsest. 2020Alveolus BioBirmingham, AL, US · est. 2020

Alveolus Bio: Innovating FDA-approved therapeutics for lung diseases.

Series A · $7M7
Lung BiotechnologyLung BiotechnologySilver Spring, MD, USPharmaceuticalsest. 1997Lung BiotechnologySilver Spring, MD, US · est. 1997

Lung Biotechnology PBC: Researching, developing, and marketing therapies for pulmonary arterial hypertension.

Public125

Russ Lehrman's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao

People Similar to Russ Lehrman

David JunckerDavid JunckerCo-Founder · Nomic BioElicia MaineElicia MaineBoard Member · Innovate BCBrian SchultzBrian SchultzCo-Founder · Union Bay PartnersBenjamin LeibowitzBenjamin LeibowitzFounder · InhouseMichael BoiceMichael BoiceCo-Founder · RepairogenJohn LeesJohn LeesCo-Founder · Trella Health